Clinical trial · Interventional
Safety and Effectiveness of Giving SU5416 to HIV-Infected Patients With AIDS-Related Kaposi's Sarcoma
A Multicenter, Dose Escalating Study in Patients With Cutaneous AIDS-Related Kaposi's Sarcoma
NCT00002226CI-TRIAL-00000097completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to see if it is safe and effective to give SU5416 to HIV-infected patients with AIDS-related Kaposi's sarcoma (KS). SU5416 may prevent the growth of KS tumors.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| HIV Infections | — | UNRESOLVED | — |
| Sarcoma, Kaposi | Kaposi Sarcoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| SU5416 | Drug | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria You may be eligible for this study if you: * Are at least 18 years old. * Are HIV-positive. * Have KS with at least 5 skin lesions. * Have been in stable condition for at least 6 weeks prior to study entry, if receiving antiretroviral therapy. * Agree to use effective methods of birth control during the study. Exclusion Criteria You will not be eligible for this study if you: * Have had surgery within 4 weeks of study entry. * Have taken certain medications, including therapy for KS, within 3 weeks prior to study entry. * Have pulmonary KS (KS in your lungs). * Have certain serious medical conditions, including liver or kidney problems, certain infections, and certain cancers. * Are allergic to Cremophor. * Have not recovered from previous cancer treatment (chemotherapy, radiotherapy, or immunotherapy). * Are pregnant.
References
Publications (1)
- BACKGROUNDGill P, Arasteh K, Jacobs M, Friedman-Kiel A, Miles S, Gracey S, Hannah A, Langecker P. A multicenter, dose-escalating study in patients with AIDS-related Kaposi's Sarcoma 39th Intersci Conf Antimicrob Agents Chemother. 1999 Sept 26-29